Report: Global market for Huntington’s disease therapeutic to record 25.6% CAGR up to 2024

19th May 2016 (Last Updated May 19th, 2016 18:30)

The Huntington’s disease market is projected to grow at a compound annual growth rate (CAGR) of 25.6% to reach $2.6bn by 2024, says a new GlobalData report. The $252.6m market is anticipated to grow globally across the US, UK, France, Germany, Italy, Spain and Japan.

The Huntington's disease market is projected to grow at a compound annual growth rate (CAGR) of 25.6% to reach $2.6bn by 2024, says a new GlobalData report. The $252.6m market is anticipated to grow globally across the US, UK, France, Germany, Italy, Spain and Japan.

Titled 'Opportunity Analyzer: Huntington's Disease - Opportunity Analysis and Forecast to 2024', the report summarises that the huge leap in the disease's treatment space will be propelled by the introduction of new disease-modifying drugs that will expand the limited treatment options currently available.

The report goes on to highlight additional factors, which will also influence the growth of this space, including advanced symptomatic treatments, improved assistance for expensive treatments and greater awareness of the disease.

The therapeutic market for the drug is relatively unexplored as there are very few approved treatment options currently available, making it an ideal investment space with vast potential. At present there are two drugs, Raptor's RP103 and Prana Biotechnology's PBT2, which are on the threshold of being launched, with the former poised to become a pioneer in the market.

"The Huntington's disease pipeline will see exciting new developments over the next decade as disease-modifying drugs transform the market landscape."

Japan is an exception in the Huntington's disease market among all the key geographies with the smallest market expansion expected in 2024, a slight improvement from $0.6m in 2014 to $1.5m. Although the figures indicate a small increase, is the Japanese market will be significant and will be driven mainly by the launch of Teva's SD-809 and pridopidine, says the report.

Rebecca Robbins, MPharmacol, GlobalData's analyst covering neurology and ophthalmology, explains: "The Huntington's disease pipeline will see exciting new developments over the next decade as disease-modifying drugs transform the market landscape.

"With ongoing research helping to further understand its pathogenesis, there are increasingly significant opportunities for developers to cultivate new drugs that may have differing modes of action from those already in the pipeline."